Relpax and Injection site bruising - a phase IV clinical study of FDA data

Summary:

Injection site bruising is reported as a side effect among people who take Relpax (eletriptan hydrobromide), especially for people who are female, 40-49 old, also take Humira, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Injection site bruising when taking Relpax. It is created by eHealthMe based on reports of 8,715 people who have side effects when taking Relpax from the FDA, and is updated regularly.

What is Relpax?

Relpax has active ingredients of eletriptan hydrobromide. It is often used in migraine. eHealthMe is studying from 9,259 Relpax users. Check the latest studies of Relpax.

What is Injection site bruising?

Injection site bruising is found to be associated with 1,064 drugs and 1,051 conditions by eHealthMe. Check the latest studies of Injection site bruising.

On Jul, 21, 2026

8,715 people reported to have side effects when taking Relpax.
Among them, 26 people (0.3%) have Injection site bruising.

Could Relpax cause Injection site bruising?

Among these 26 people:

What is the gender of people who have Injection site bruising when taking Relpax? *

female: 84.62 %
male: 15.38 %

What is the age of people who have Injection site bruising when taking Relpax? *

What are other drugs people take besides Relpax? *

What are other side effects people have besides Injection site bruising? *

Injection Site Pain: 12 people, 46.15%
Injection Site Erythema (redness at injection site): 7 people, 26.92%
Drug Ineffective: 6 people, 23.08%
Injection Site Irritation: 4 people, 15.38%
Joint Pain: 3 people, 11.54%
Injection Site Pruritus (severe itching at injection site): 3 people, 11.54%
Chest Pain: 3 people, 11.54%
Prostate Cancer: 2 people, 7.69%
Breast Pain: 2 people, 7.69%
Injection Site Urticaria (rash of round, red welts on the skin at injection site): 2 people, 7.69%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 23.08%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 23.08%
Stress And Anxiety: 3 people, 11.54%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 11.54%
Dry Eyes (lack of adequate tears): 2 people, 7.69%
Pain: 2 people, 7.69%
Irritable Bowel Syndrome: 2 people, 7.69%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 7.69%
Osteoporosis (bones weak and more likely to break): 2 people, 7.69%
High Blood Pressure: 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Relpax and have Injection site bruising?

- Check whether Injection site bruising is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Relpax:

Relpax (9,259 reports)

Browse all side effects of Relpax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site bruising:

Injection site bruising (1,064 drugs)

Browse all the conditions that are associated with Injection site bruising:

Injection site bruising (1,051 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eletriptan hydrobromide (the active ingredients of Relpax) and Relpax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.